Core Insights - ProteoNic BV's proprietary 2G UNic® technology has been licensed by Ginkgo Bioworks for a project funded by BARDA, aimed at enhancing domestic biomanufacturing of monoclonal antibodies to combat filoviruses like Ebola and Sudan Virus [1][2] Group 1: Project Overview - The project has a total value of up to $22.2 million and involves a collaboration between Ginkgo Bioworks, Advanced BioScience Laboratories, Isolere Bio, NeuImmune, and ProteoNic [2] - The initiative focuses on developing innovative technologies across the entire monoclonal antibody production process, from cell line development to purification, to create a more efficient and cost-effective biomanufacturing solution [2] Group 2: ProteoNic's Role - ProteoNic's contribution centers on its 2G UNic vector and transposon technologies, which are designed to maximize expression and productivity in mammalian systems, thereby enhancing manufacturing efficiency and yield [3] - The technology aims to reduce both time and cost associated with large-scale bioproduction of monoclonal antibodies [3] Group 3: Strategic Importance - The collaboration highlights ProteoNic's expansion into next-generation biologics manufacturing, supporting therapeutic protein production and cell and gene therapy applications [4] - By improving productivity from existing manufacturing infrastructure, ProteoNic's technology aims to bolster biomanufacturing resilience against future global health threats [4]